scholarly journals Overview of therapeutic options in COVID-19

2021 ◽  
Vol 58 (2) ◽  
pp. 669-677
Author(s):  
Sarthak Katyal, Dr. Swarupa Chakole
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Preventive Measures ◽  
Respiratory Disorder ◽  
The Novel ◽  
Disease Avoidance ◽  
The World ◽  
The City

Coronavirus is essentially a respiratory sickness brought about by a newfound rSARS-CoV-2 infection and distinguished in the city of Wuhan, China in December 2019. The emerging outbreak of Covid disease 2019 (COVID-19) brought about because ofthe severe respiratory disorder Covid 2 (SARS-CoV-2) presents a phenomenal test for medical services frameworks around the world.WHO has proclaimed this illness as a pandemic, and cautioned different nations. Like other Covids, this may create respiratory plot contaminations in the patients range from gentle to lethal ailment like pneumonia and ARDS(acute respiratory distress syndrome).The features of coronavirus and the capacity to quickly make far reaching contamination has significant ramifications, justifying vivacious disease avoidance and the preventive measures. While the affirmed quantity of the cases have outperformed 10.3 million throughout the world and keeps on developing, as the possible seriousness related to infection along  with its destructive confusions needs critical advancement of the novel restorative specialists to both forestall and cure the COVID-19 illness . In spite of the fact that antibodies and explicit medication treatments presently can't seem to be found, progressing investigation and subjective preliminaries have led to the examination of viability of the  reused medications for curing COVID-19 illness .According to the current audit, some of the medication competitors have been recommended to cure  COVID-19 will be talked about. While these incorporate enemy of the viral specialists (remdesivir ,rebetol, lopinavir-ritonavir,choloroquine, favipiravir, hydroxychloroquine, umifenovir ,oseltamivir,), immunomodulating based specialists (interferons, plasma bondings , tocilizumab), (azithromycin, corticosteroids),  along with other random specialists. With components of activity and further pharmacology based property which should be investigated, within a specific spotlight on the proof  base wellbeing with viability of a every specialist.

scholarly journals Atypical facial onset Guillain-Barré syndrome following first dose of COVISHIELD vaccine

2021 ◽  
Vol 20 (3) ◽  
pp. 379-382
Author(s):  
R.V. Aravinda ◽  
◽  
Priyanka Mahendra Tater ◽  
Harsha Huliyappa ◽  
Christy Joseph Manual ◽  
...  
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Guillain Barre Syndrome ◽  
Significant Morbidity ◽  
Global Pandemic ◽  
The World ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

In the midst of the global pandemic of COVID-19 and its significant morbidity and mortality reported across the world due to severe acute respiratory distress syndrome (SARS), it has always been posing a new set of complications each passing day. As we are still in the process of understanding about the complications related to COVID-19, we are encountered with complications related to immunization for COVID-19. We are reporting a case of facial onset Guillain-Barré syndrome (GBS) in the patient who received first dose of COVISHIELD vaccine a couple of weeks prior to the onset of his illness.

scholarly journals Pediatric Acute Respiratory Distress Syndrome (PARDS) On Pediatric COVID-19 Patients

2021 ◽  
Vol 1 (2) ◽  
pp. 147-157
Author(s):  
Siti Rahmah ◽  
Lalu Wahyu Alfian Muharzami ◽  
Lastri Akhdani Almaesy ◽  
Putri Nurhayati ◽  
Ridha Sasmitha A
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Virus Transmission ◽  
The Novel ◽  
Handling Technique ◽  
The Difference ◽  
One Year ◽  
Novel Coronavirus

At the end of 2019, there was a pandemic happening in the world, called the novel Coronavirus disease-19 (COVID-19). Various spectrums of disease from COVID-19, one of which is ARDS. The incidence of COVID-19 in children is not as much as in adults. However, in children under one year of age it can get worse. The main characteristic of worsening infection is the occurrence of ARDS.  Objective: To find out the best treatment for PARDS in COVID-19 patients. Method: The writing of this article uses various sources from scientific journals to government guidelines and related institutions. Search articles using the keywords “Acute Respiratory Distress Syndrome”, “ARDS”, “Pediatric Respiratory Distress Syndrome”, “PARDS”, and “PARDS on COVID-19” Result and Discussion: PARDS was defined based on PALICC in 2015. Pathophysiology of PARDS in COVID-19 patients is still unclear. However, there is a theory that explains the way SARS-Cov-2 enters cells, namely through membrane fusion, giving rise to ARDS. The difference in handling PARDS for COVID-19 patients is that the handling technique is more alert to the risk of aerosols. Conclusions: There are differences in the handling of PARDS for COVID-19 patients in the technique by reducing the risk of virus transmission by preventing leakage when using a ventilator and using a bacterial/virus filter, as well as rescuers and staff using complete PPE during the procedure.

The chance of COVID-19 infection after vaccination

2022 ◽  
Vol 22 ◽  
Author(s):  
Ghazaleh Khalili-Tanha ◽  
Majid Khazaei ◽  
Saman Soleimanpour ◽  
Gordon A Ferns ◽  
Amir Avan
Keyword(s):  
Genetic Diversity ◽  
Immune Response ◽  
Acute Respiratory Distress Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Mild Form ◽  
The World ◽  
New Generation ◽  
Pathogenic Infection

Abstract: The outbreak of COVID-19 that began in Wuhan, China, has constituted a new emerging epidemic that has spread around the world. There are some reports on illustrated the patients getting reinfected after recovering from COVID-19. Here we provide an overview of the biphasic cycle of COVID-19, genetic diversity, immune response and chance of reinfection after recovering from COVID-19. The new generation of COVID-19 is highly contagious and pathogenic infection can lead to acute respiratory distress syndrome. Whilst most patients suffer from a mild form of the disease, there is a rising concern that patients who recover from COVID-19 may be at risk of reinfection. The proportion of the infected population, is increasing worldwide; meanwhile, the rate and concern of reinfection by the recovered population are still high. Moreover, there are a few evidence on the chance of COVID-19 infection even after vaccination, which is around one per cent or less. Although the hypothesis of zero reinfections after vaccination has not been clinically proven, further studies should be performed on the recovered class in clusters to study the progression of the exposed with the re-exposed subpopulations to estimate the possibilities of reinfection and, thereby, advocate the use of these antibodies for vaccine creation.

Acute Respiratory Distress Syndrome (ARDS) Caused by the Novel Coronavirus Disease (COVID-19): A Practical Comprehensive Literature Review

2020 ◽  
Author(s):  
Francisco Montenegro ◽  
Luis Unigarro ◽  
Gustavo Paredes ◽  
Tatiana Moya ◽  
Ana Romero ◽  
...  
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Literature Review ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Clinical Manifestations ◽  
The Novel ◽  
Comprehensive Literature Review ◽  
Wide Range ◽  
Novel Coronavirus

Introduction: The exponential growth of the SARS-CoV-2 virus transmission during the first months of 2020 has placed substantial pressure on health systems worldwide. The complications derived from the novel coronavirus disease (COVID-19) vary in due to comorbidities, sex and age, with more than 50% of the patients who require some level of intensive care developing acute respiratory distress syndrome (ARDS). Areas covered: Various complications caused by SARS-CoV-2 infection have been identified, the most lethal being the acute respiratory distress syndrome, caused most likely by the presence of severe immune cell response and the concomitant alveolus inflammation. The authors carried out an extensive and comprehensive literature review on SARS-CoV-2 infection, the clinical, pathological and radiological presentation as well as the current treatment strategies. Expert Opinion Elevation of inflammatory biomarkers is a common trend among seriously ill patients. The information available strongly suggests that in COVID-19 patients, their altered immune response, including a massive cytokine storm, is responsible for the further damage evidenced among ARDS patients. The increasingly high number of scientific articles and evidence available can only suggest that the individualization of each case is the norm, not all patients with acute respiratory failure due to COVID-19 meet the Berlin definition and therefore ARDS should be considered as a heterogeneous disease, with a wide range in the expression of its severity and clinical manifestations.

scholarly journals Multiorgan Involvement in COVID-19 and Possible Therapies

2020 ◽  
Vol 04 (01) ◽  
pp. 20-24
Author(s):  
Prachee Sathe ◽  
Vijay Sundar Singh
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
World Health Organization ◽  
Distress Syndrome ◽  
Respiratory Illness ◽  
World Health ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization

AbstractIn late 2019, China reported cases of respiratory illness in humans, which involved a novel Coronavirus SARS-CoV-2 (also known as 2019-nCoV). The World Health Organization (WHO) termed the disease COVID-19 (i.e., Coronavirus disease 2019). Most of the morbidity and mortality from COVID-19 is largely due to acute viral pneumonitis that leads to acute respiratory distress syndrome (ARDS). This article will discuss the clinical features of the multiorgan involvement in COVID-19 as well as the management of patients who become critically ill due to COVID-19.

scholarly journals Prone ventilation in COVID-19 acute respiratory distress syndrome: Case report of two patients from Ethiopia

2021 ◽  
Vol 0 ◽  
pp. 1-4
Author(s):  
Dawit Kebede Huluka ◽  
Sebrina Ahmed ◽  
Hiwotie Abebe ◽  
Joseph Huang ◽  
David H. Chong ◽  
...  
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Invasive Mechanical Ventilation ◽  
Mortality Benefit ◽  
Resource Limited Settings ◽  
Resource Limited ◽  
The World ◽  
Supportive Management

The COVID-19 pandemic is one of the largest health crises that the world has ever seen, infecting forty million people and killing more than 1 million to date. The disease has imposed a significant demand on health care resources due to the increased number and severely ill patients visiting facilities each day. Since there is no effective cure for COVID-19, supportive management with oxygen, steroids, anticoagulation, and prone positioning remains the major interventions. Prone ventilation is known to have a mortality benefit in intubated patients with acute respiratory distress syndrome (ARDS). However, studies on its role in intubated patients with COVID-19 ARDS (CARDS) are very scarce in resource-limited settings like Africa. We describe two patients with CARDS who were successfully treated with invasive mechanical ventilation, prone ventilation, and standard supportive care.

The Promise of Mesenchymal stem cells therapy for acute Respiratory Distress Syndrome Caused by COVID-19

2020 ◽  
Vol 15 ◽  
Author(s):  
Jundong Gu ◽  
Qinjun Zhao ◽  
Zhibo Han ◽  
Zhongchao Han
Keyword(s):  
Stem Cells ◽  
Acute Respiratory Distress Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Public Health Problem ◽  
Preclinical Models ◽  
The World ◽  
Stem Cells Therapy ◽  
General Mortality

: The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) since Dec 2019, known as COVID-19 or 19-nCoV, has led to a major concern of the potential for not only an epidemic but a pandemic in China and now it seems to be a public health problem all over the world. The general mortality rate of the COVID-19 was about 3%. However, the mortality risk seems to be a significant increase in elderly and cases with chronic disease, who are more likely to develop into acute respiratory distress syndrome (ARDS). There still lacks effective methods for ARDS of COVID-19 patients and the prognosis was poor. Mesenchyma stem cells (MSCs) based treatment has the advantage of targeting numerous pathophysiological components of ARDS by secreting a series of cell factors, exerting anti-inflammatory, antioxidative, immunomodulatory, antiapoptotic, and proangiogenic effects, resulting in significant structural and functional recovery following ARDS in various preclinical models. And recently pilot clinical studies indicated MSCs based therapy was promise in treatment of ARDS caused by SARS-CoV-2. However, little is known about MSCs therapy for ARDS caused by COVID-19.

scholarly journals Transportation of Food by Cold Chain Methods one of the Cause of Reoccurrence Covid-19 Infection during its Pandemic

2021 ◽  
Vol 9 (12) ◽  
pp. 2376-2378
Author(s):  
Mesut Selamoğlu ◽  
Ali Raza Memon
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Viral Infection ◽  
Distress Syndrome ◽  
Morbidity And Mortality ◽  
Cold Chain ◽  
Corona Virus ◽  
The World ◽  
Second Wave

The Corona Virus is the pandemic all over the world. This viral infection attacked all over the world like as disaster of viral infection which causes morbidity and mortality in different regions of world like Asia, Europe, and Africa etc. The different countries control the spread and complications of covid-19 like Acute Respiratory Distress Syndrome in well manner. In second wave there was again out break of covid-19 some regions of world. Here we discuss the causes of reoccurrence and their preventive measurements from our break effects of Covid-19.

Sign in / Sign up

Export Citation Format

Share Document